LifeArc's Chief Scientific Officer calls for UK science to continue to be a contributor to the Horizon Europe programme.
The new antibody offers hope of an effective new treatment option for millions of people.
Unique translational research hub for Covid-19 and other viruses was a finalist in the Scottish Knowledge Exchange Awards.
Welcome to Dr Dave Powell, who has joined LifeArc as our first Chief Scientific Officer (CSO). Dave is an experienced scientist and leader, with…
An antibody-based treatment and protein-based vaccine reduced Alzheimer’s symptoms in mouse models of the disease.
This week, results from the 100,000 Genomes Project showed that whole genome sequencing improves the diagnosis of…
How LifeArc aims to support charities, researchers and funders exploring new uses for existing medicines
Former Innovate UK Executive Chair joins charity to drive new collaborations and partnerships to benefit patient health.
LifeArc boosts investment in Cambridge University spin-out PolyProx Therapeutics to advance new class of cancer medicines
The investment will help advance studies to validate polyproxin® molecules as potential drug candidates across a range of cancers.